Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

VX-272

Other · developed by VERTEX PHARMACEUTICALS INC / MA

Phase 1 Most advanced trial
VRTX Developer
1 Registered trials

What is VX-272?

VX-272 is an investigational drug studied in Cystic Fibrosis.

At a glance

Drug type
Other
Therapy area
Respiratory
Developer
VERTEX PHARMACEUTICALS INC / MA (VRTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07437105 Phase 1 Cystic Fibrosis Recruiting VRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic Fibrosis

More from VERTEX PHARMACEUTICALS INC / MA

Deutivacaftor FDA approved Elexacaftor FDA approved Exagamglogene Autotemcel FDA approved Ivacaftor FDA approved Suzetrigine FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved Inaxaplin Phase 2/3 Povetacicept Phase 2/3 VX-017 Phase 3 VX-118 Phase 1 VX-264 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the VRTX page.

Follow VRTX, the company behind VX-272

See VRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.